Andere talen Quince Therapeutics, Inc.

Aandelen

QNCX

US22053A1079

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,06 ^USD	+2,91%		+0,95%	+0,95%

01/04	Quince Therapeutics, Inc. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
26/03	Transcript : Quince Therapeutics, Inc. - Special Call

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results	01/04
North American Morning Briefing : Markets Steady -2-	26/03
Quince Therapeutics Launches Scientific Advisory Board	22/02
Quince Therapeutics, Inc. Launches Scientific Advisory Board	22/02
Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors	15/02
Quince Therapeutics, Inc. Appoints Rajiv Patni to Its Board of Directors	15/02
Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference	07/02
Quince Therapeutics to Participate at Investor Events in January 2024	04/01
North American Morning Briefing : All Eyes on -2-	21/11
Quince Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Quince Therapeutics : Investor Presentation – November 2023	06/11
Quince Therapeutics, Inc. Appoints Brendan Hannah to the Position of Chief Operating Officer	26-10-23
Quince Therapeutics, Inc. Appoints Luca Benatti as Director	23-10-23
Quince Therapeutics Completes Acquisition of EryDel S.p.A.	23-10-23
Quince Therapeutics, Inc. acquired EryDel S.p.A	23-10-23
Quince Says US FDA Lifts Partial Clinical Hold on EryDel's Treatment for Ataxia-Telangiectasia	28-09-23
Quince Therapeutics to Advance Study of EryDex as FDA Lifts Application Hold	28-09-23
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia	28-09-23
Quince Therapeutics, Inc. Announces That U.S. Food and Drug Administration Lifts the Partial Clinical Hold on Erydel S.P. A's Investigational New Drug Application for Its Lead Phase 3 Asset, Erydex	28-09-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Quince Therapeutics, Inc.

Aandelen

QNCX

US22053A1079

Andere talen

Filters